BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

A new drug application (NDA) that FDA lists in Drugs@FDA, with an original approval and no efficacy supplement approvals on record.

  • Product
  • In this atlas

Overview

Technical summary

Drugs@FDA application NDA208374. Original approval 2017-12-21. No efficacy supplement approvals are on record. 2 products listed.

Trials at a glance

No registry trial in this atlas names this product.

Regulatory decisions
1

Product details

Type
Medicine
Model or formulation
Dosage forms in the registry record: SOLUTION
Version
Not stated in the openFDA record

Intended-use sources

No intended-use source is recorded.

The registry's words

Labels as the registry gives them, not rewritten.

Application
NDA208374
Brand name
BIVALIRUDIN IN 0.9% SODIUM CHLORIDE
Applicant
BAXTER HLTHCARE CORP
Active ingredient
BIVALIRUDIN
Dosage form
SOLUTION
Route
INTRAVENOUS

Claims and evidence

Context FDA record read by the openFDA feed

Recipient
Recipient not specified
Population
Not stated in the openFDA record
Care setting
Not stated in the openFDA record
Geography
United States (a decision by the US Food and Drug Administration)
Life stage
Not stated in the openFDA record
Gestational age
Not reported
Postnatal age
Not reported
Follow-up
Not applicable (regulatory decision)
Eligibility: inclusion criteria not stated; exclusion criteria not stated
Included
None stated
Excluded
None stated
  • Regulatory Evidence stage not applicable Certainty not assessed

    FDA records an approval of NDA208374 on 2017-12-21.

    Applies to Recipient not specified FDA record read by the openFDA feed

    Certainty method
    Not assessed
    Limitations
    Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.
    Last checked
    Not recorded
    Next evidence check due
    Not scheduled
    Sources and citations (3)
    1. Supports Drugs@FDA application NDA208374 (openFDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · NDA: NDA208374

      Locator
      submissions[0].submission_status_date
      How it applies
      The decision date as the record writes it.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      97d76cf49329605d0d90ffd0163adfe37b9bed732674e2bcb8ae8f99dc550da1
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
    2. Supports Drugs@FDA application NDA208374 (openFDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · NDA: NDA208374

      Locator
      application_number
      How it applies
      The registry number of the record.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      97d76cf49329605d0d90ffd0163adfe37b9bed732674e2bcb8ae8f99dc550da1
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.
    3. Supports Drugs@FDA application NDA208374 (openFDA record)

      Regulator · U.S. Food and Drug Administration (openFDA) · NDA: NDA208374

      Locator
      submissions[0].submission_status
      How it applies
      The decision status as the record writes it.
      Retrieved
      Source effective date
      Not reported
      Source state
      Current
      Version fingerprint
      97d76cf49329605d0d90ffd0163adfe37b9bed732674e2bcb8ae8f99dc550da1
      Reuse basis
      openFDA data is public domain under a Creative Commons CC0 1.0 Universal dedication unless noted (https://open.fda.gov/license/). openFDA says its data is unvalidated and not for medical decisions. The feed commits an extract of the fields it reads, without contact names or addresses, and keeps the raw answer in a private archive named by its sha256.

FDA label

The FDA label of the application holder, as the openFDA label dataset holds it, for this product.

No label from the application holder was found in the openFDA label dataset for application NDA208374. This page does not show another labeler's label in its place.

FDA decisions timeline

The regulatory decisions of the FDA that this atlas holds for this product, oldest first. Each links to its full record.

  1. Approval NDA208374

Authorization

Regulatory decision: BIVALIRUDIN IN 0.9% SODIUM CHLORIDE

Applies to Recipient not specified
  • Not stated in the openFDA record
  • Not stated in the openFDA record
  • United States (a decision by the US Food and Drug Administration)
  • Not stated in the openFDA record
  • Gestational age Not reported
  • Postnatal age Not reported
Follow-up Not applicable (regulatory decision)
Decision
Approval,
Pathway
NDA
Submission
NDA208374
Jurisdictions
United States
Product version
Original application
Indication
Not stated in the openFDA record
Basis
FDA records an approval of NDA208374 on 2017-12-21.

Limitations. Assembled by a program from openFDA; the approved uses are in the FDA label, which this record does not read. openFDA says its data is unvalidated and not for medical decisions.

A regulatory decision is separate from a guideline recommendation and from payment coverage.

Record details

Record id
cardio:fdaprod-nda208374
Content hash
6fda3860c8a8b7d2726419cfe1d250ac4e46ce85f3f2cff279566dc3245fd6bf